SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Alembic Pharmaceuticals gains after its arm gets nod for Investigational New Drug application

02 Dec 2020 Evaluate

Alembic Pharmaceuticals is currently trading at Rs. 992.05, up by 6.75 points or 0.69% from its previous closing of Rs. 985.30 on the BSE.

The scrip opened at Rs. 985.00 and has touched a high and low of Rs. 1005.25 and Rs. 981.90 respectively. So far 7411 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1128.00 on 07-Aug-2020 and a 52 week low of Rs. 436.10 on 23-Mar-2020.

Last one week high and low of the scrip stood at Rs. 1018.00 and Rs. 974.25 respectively. The current market cap of the company is Rs. 19530.51 crore.

The promoters holding in the company stood at 69.77%, while Institutions and Non-Institutions held 16.46% and 13.76% respectively.

Alembic Pharmaceuticals’ step down wholly owned subsidiary -- Rhizen has received approval from US Food and Drug Administration (USFDA) for its Investigational New Drug (IND) application to study its oral DHODH inhibitor for SARS-CoV-2 infection. The initial study shall evaluate single ascending doses of RP7214 in healthy volunteers and that dosing is expected to commence in early December 2020.

Dihydroorotate dehydrogenase (DHOHD) is a key enzyme involved in pyrimidine biosynthesis in the cell. RP7214 is potentially a best-in-class selective DHODH inhibitor that has shown potent inhibition of Covid19 viral replication.

Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has been at the forefront of Healthcare since 1907.

Alembic Pharma Share Price

784.95 36.05 (4.81%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×